Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% weight loss. Data from a late-stage trial is expected by end of 2024. The company's shares could rise or fall by 20% based on the trial's success.

The pharmaceutical giant’s blockbuster weight-loss drug beat sales expectations in the third quarter, sending shares higher in early trade.

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs.

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may have overestimated the market for its new weight-loss and diabetes medicines.

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs Wegovy and Ozempic, its CFO Karsten Munk Knudsen told a media

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. The company is still "evaluating" the price of the drug,